Overall, the prominent presence of bFGF is negatively correlated with ESCC and EAC patients’ outcomes, increasing the risk of relapses as well as reducing overall survival post-surgical resection [81,82]. The gene discussed is FGF2; the disease is esophageal squamous cell carcinoma.